These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 19949090)
21. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927 [TBL] [Abstract][Full Text] [Related]
22. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
23. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Sloat BR; Cui Z Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937 [TBL] [Abstract][Full Text] [Related]
24. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777 [TBL] [Abstract][Full Text] [Related]
25. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
26. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Bracci L; Canini I; Puzelli S; Sestili P; Venditti M; Spada M; Donatelli I; Belardelli F; Proietti E Vaccine; 2005 Apr; 23(23):2994-3004. PubMed ID: 15811645 [TBL] [Abstract][Full Text] [Related]
27. Immune response after adjuvant mucosal immunization of mice with inactivated influenza virus. Zanvit P; Havlícková M; Tácner J; Jirkovská M; Petrásková P; Novotná O; Cechová D; Julák J; Sterzl I; Prokesová L Immunol Lett; 2005 Mar; 97(2):251-9. PubMed ID: 15752565 [TBL] [Abstract][Full Text] [Related]
28. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
29. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model. Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250 [TBL] [Abstract][Full Text] [Related]
30. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Jalava K; Eko FO; Riedmann E; Lubitz W Expert Rev Vaccines; 2003 Feb; 2(1):45-51. PubMed ID: 12901596 [TBL] [Abstract][Full Text] [Related]
31. Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response. Zhang P; Chiu YC; Tostanoski LH; Jewell CM ACS Nano; 2015 Jun; 9(6):6465-77. PubMed ID: 26035231 [TBL] [Abstract][Full Text] [Related]
32. Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. De Geest BG; Willart MA; Lambrecht BN; Pollard C; Vervaet C; Remon JP; Grooten J; De Koker S Angew Chem Int Ed Engl; 2012 Apr; 51(16):3862-6. PubMed ID: 22411781 [TBL] [Abstract][Full Text] [Related]
34. Polysaccharide-based vaccine delivery systems: Macromolecular assembly, interactions with antigen presenting cells, and in vivo immunomonitoring. Weber C; Drogoz A; David L; Domard A; Charles MH; Verrier B; Delair T J Biomed Mater Res A; 2010 Jun; 93(4):1322-34. PubMed ID: 19859973 [TBL] [Abstract][Full Text] [Related]
35. Encapsulation of basic fibroblast growth factor by polyelectrolyte multilayer microcapsules and its controlled release for enhancing cell proliferation. She Z; Wang C; Li J; Sukhorukov GB; Antipina MN Biomacromolecules; 2012 Jul; 13(7):2174-80. PubMed ID: 22657385 [TBL] [Abstract][Full Text] [Related]
37. Opportunities and challenges of the pulmonary route for vaccination. Blank F; Stumbles P; von Garnier C Expert Opin Drug Deliv; 2011 May; 8(5):547-63. PubMed ID: 21438741 [TBL] [Abstract][Full Text] [Related]
38. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents. Eng NF; Garlapati S; Gerdts V; Potter A; Babiuk LA; Mutwiri GK Curr Drug Deliv; 2010 Jan; 7(1):13-20. PubMed ID: 19863483 [TBL] [Abstract][Full Text] [Related]